_×
  0 products, total $0.+86-400-890-9989      Login |  Register 中文한국어

Browse By Molecule:

Your Position: Home > Antibody > Rabbit MAb Antibody > 4-1BBL / CD137L / TNFSF9 Antibody ( FITC )

4-1BBL / CD137L / TNFSF9 Antibody ( FITC ) (Cytokine) PDF Download

Catalog Size (Price) Quantity In Stock Operation Other Information
50067-R014-F
  YES          

4-1BBL / CD137L / TNFSF9 Antibody Datasheet

  Order or Inquire for 4-1BBL / CD137L / TNFSF9 Antibody product Quality antibodies Antibody production services
 

4-1BBL / CD137L / TNFSF9 Antibody Product Information

Immunogen :

Recombinant Mouse 4-1BBL / CD137L / TNFSF9 protein (Catalog#50067-M07H)

Reagents : FITC-conjugated rabbit monoclonal antibody

Clone ID :

014

Ig Type :

Rabbit IgG

Concentration :

10 μl/Test, 0.1 mg/ml

Formulation : Aqueous solution containing 0.5% BSA and 0.09% sodium azide
Preparation :

This antibody was obtained from a rabbit immunized with purified, recombinant Mouse 4-1BBL / CD137L / TNFSF9 (rM 4-1BBL / CD137L / TNFSF9; Catalog#50067-M07H; NP_033430.1; Arg 104-Glu 309) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.

4-1BBL / CD137L / TNFSF9 Antibody Usage Guide

Specificity :

Mouse 4-1BBL / CD137L / TNFSF9

Flow Cytometry :
4-1BBL / CD137L / TNFSF9 Flow Cytometry

Profile of anti-TNFSF9 reactivity on Raw264.7 cells analyzed by flow cytometry. Cells should be Fc-blocked by treatment with Mouse BD Fc Block™ purified anti-CD16/CD32 mAb 2.4G2 (Cat. No. 553141) prior to staining, washed, then stained with FITC Rabbit anti-TNFSF9.

Flow cytometry was performed on a BD FACSCalibur flow cytometry system

Please refer to www.sinobiological.com/Flow-Cytometry-FACS-Protocols-a-750.html for technical protocols.

Storage : This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

4-1BBL / CD137L / TNFSF9 Antibody Related Products & Topics

4-1BBL / CD137L / TNFSF9 Antibody Related Areas:

Immunology>>Adaptive Immunity>>Costimulation & Costimulatory Molecule>>4-1BBL/CD137L/TNFSF9

Immunology>>Cytokine & Receptor>>TNF Superfamily>>4-1BBL/CD137L/TNFSF9

Immunology>>Cluster of Differentiation>>B Cell CD Antigen>>4-1BBL/CD137L/TNFSF9

Proteins:

Molecule Species Description //For Detailed Info. and Price------CLICK! Cat. No
4-1BBL/CD137L Mouse 4-1BBL/CD137L Protein, Recombinant 50067-M07H
4-1BBL/CD137L Rat TNFSF9 Protein, Recombinant 80166-R01H
4-1BBL/CD137L Rat TNFSF9 Protein, Recombinant 80166-R07H

Antibodies:

Molecule Application Description //For Detailed Info. and Price------CLICK! Cat. No
Mouse
4-1BBL/CD137L
WB, ELISA Rabbit Monoclonal Antibody 50067-R014
Mouse
4-1BBL/CD137L
FCM 4-1BBL / CD137L / TNFSF9 Antibody ( FITC ) 50067-R014-F
Mouse
4-1BBL/CD137L
ELISA Rabbit Polyclonal Antibody 50067-RP01
Mouse
4-1BBL/CD137L
WB, ELISA Rabbit Polyclonal Antibody 50067-RP02

4-1BBL / CD137L / TNFSF9 Antibody Background

4-1BB ligand (4-1BBL), also known as TNFSF9, is a member of the tumor necrosis factor (TNF) superfamily (TNFSF), and interacts with 4-1BB (CDw137) expressed on activated T cells and delivers a costimulatory signal for T cell activation and growth. Mouse 4-1BBL is a 309 amino acid (aa) residues protein with an 82 aa N-terminal cytoplasmic domain, a 21 aa transmembrane domain and a 206 aa C-terminal extracellular domain. The extracellular domain of 4-1BBL has a tertiary structure similar to that other TNFSF members, but shares only low aa sequence homology (14 - 16%). Murine 4-1BBL shares 36% aa sequence identity with its human counterpart which is detected in both T and B cells of human peripheral blood. 4-1BB ligand interacts with 4-1BB and co-stimulates the latter to secrete cytokines and to proliferate, and also this interaction modulates the effector CD4+ T cell-driven immune response and cytokine production in colitis without affecting regulatory T cell function.

References

  1. Goodwin, R.G. et al., 1993, Eur. J. Immunol. 23: 2631-2641.
  2. Alderson, M.R. et al., 1994, Eur. J. Immunol. 24: 2219-2227.
  3. Zhou, Z.et al., 1995, Immunol. Lett. 45 (1-2): 67-73.
  4. Futagawa, T. et al., 2002, Int Immunol. 14 (3): 275-286.
  5. Yoshida,H. et al., 2003, Cancer Immunol Immunother.52 (2): 97-106.
  6. Maerten, P. et al., 2006, Clin Exp Immunol.143 (2): 228-236.
 

 

Primary Antibody Products